Cargando…

Application of Bevacizumab Combined With Chemotherapy in Patients With Colorectal Cancer and Its Effects on Brain-Gut Peptides, Intestinal Flora, and Oxidative Stress

OBJECTIVE: To investigate the efficacy of bevacizumab combined with chemotherapy in the treatment of colorectal cancer (CRC) and to analyze the effects on brain peptides, intestinal flora, and oxidative stress in CRC patients. METHODS: Eighty two patients with CRC who were admitted to our hospital f...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Chao, Hou, Songtao, Zhao, Fei, Wu, Bin, Liu, Tingting, Zhang, Zhao, Li, Yuwei, Li, Hongchao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035672/
https://www.ncbi.nlm.nih.gov/pubmed/35478726
http://dx.doi.org/10.3389/fsurg.2022.872112
_version_ 1784693347374333952
author Chen, Chao
Hou, Songtao
Zhao, Fei
Wu, Bin
Liu, Tingting
Zhang, Zhao
Li, Yuwei
Li, Hongchao
author_facet Chen, Chao
Hou, Songtao
Zhao, Fei
Wu, Bin
Liu, Tingting
Zhang, Zhao
Li, Yuwei
Li, Hongchao
author_sort Chen, Chao
collection PubMed
description OBJECTIVE: To investigate the efficacy of bevacizumab combined with chemotherapy in the treatment of colorectal cancer (CRC) and to analyze the effects on brain peptides, intestinal flora, and oxidative stress in CRC patients. METHODS: Eighty two patients with CRC who were admitted to our hospital from March 2018 to June 2021 were selected as the research subjects and divided into the control group (n = 41) and the observation group (n = 41). The control group was treated with XELOX chemotherapy, and the observation group was additionally treated with bevacizumab, which was repeated every 3 weeks for a total of two treatments. The therapeutic effects of the two groups were evaluated after treatment. The brain-gut peptide index, intestinal flora index and oxidative stress index were detected, and the adverse reactions of the two groups were recorded. RESULTS: In the control group, ER was 36.59% (15/41) and DCR was 73.17% (30/41). In the observation group, ER was 63.41% (26/41) and DCR was 90.24% (37/41). ER and DCR in the observation group were higher than those in the control group (P < 0.05). After treatment, the levels of motilin and gastrin in the observation group were lower than those in the control group, and ghrelin was higher than that in the control group (P < 0.05). After treatment, the levels of Bifidobacterium, Lactobacilli and Enterococcus in the observation group were higher than those in the control group, and the level of Escherichia coli was lower than that in the control group (P < 0.05). After treatment, the SOD level of the observation group was lower than that of the control group, and the MDA level was higher than that of the control group. CONCLUSION: Bevacizumab combined with chemotherapy has good efficacy in the treatment of colorectal cancer patients, which can effectively improve the gastrointestinal motility of patients, regulate the intestinal flora of the body, rebuild the microecological balance, effectively reduce the oxidative stress response of patients, and reduce the incidence of adverse reactions.
format Online
Article
Text
id pubmed-9035672
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90356722022-04-26 Application of Bevacizumab Combined With Chemotherapy in Patients With Colorectal Cancer and Its Effects on Brain-Gut Peptides, Intestinal Flora, and Oxidative Stress Chen, Chao Hou, Songtao Zhao, Fei Wu, Bin Liu, Tingting Zhang, Zhao Li, Yuwei Li, Hongchao Front Surg Surgery OBJECTIVE: To investigate the efficacy of bevacizumab combined with chemotherapy in the treatment of colorectal cancer (CRC) and to analyze the effects on brain peptides, intestinal flora, and oxidative stress in CRC patients. METHODS: Eighty two patients with CRC who were admitted to our hospital from March 2018 to June 2021 were selected as the research subjects and divided into the control group (n = 41) and the observation group (n = 41). The control group was treated with XELOX chemotherapy, and the observation group was additionally treated with bevacizumab, which was repeated every 3 weeks for a total of two treatments. The therapeutic effects of the two groups were evaluated after treatment. The brain-gut peptide index, intestinal flora index and oxidative stress index were detected, and the adverse reactions of the two groups were recorded. RESULTS: In the control group, ER was 36.59% (15/41) and DCR was 73.17% (30/41). In the observation group, ER was 63.41% (26/41) and DCR was 90.24% (37/41). ER and DCR in the observation group were higher than those in the control group (P < 0.05). After treatment, the levels of motilin and gastrin in the observation group were lower than those in the control group, and ghrelin was higher than that in the control group (P < 0.05). After treatment, the levels of Bifidobacterium, Lactobacilli and Enterococcus in the observation group were higher than those in the control group, and the level of Escherichia coli was lower than that in the control group (P < 0.05). After treatment, the SOD level of the observation group was lower than that of the control group, and the MDA level was higher than that of the control group. CONCLUSION: Bevacizumab combined with chemotherapy has good efficacy in the treatment of colorectal cancer patients, which can effectively improve the gastrointestinal motility of patients, regulate the intestinal flora of the body, rebuild the microecological balance, effectively reduce the oxidative stress response of patients, and reduce the incidence of adverse reactions. Frontiers Media S.A. 2022-04-11 /pmc/articles/PMC9035672/ /pubmed/35478726 http://dx.doi.org/10.3389/fsurg.2022.872112 Text en Copyright © 2022 Chen, Hou, Zhao, Wu, Liu, Zhang, Li and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Surgery
Chen, Chao
Hou, Songtao
Zhao, Fei
Wu, Bin
Liu, Tingting
Zhang, Zhao
Li, Yuwei
Li, Hongchao
Application of Bevacizumab Combined With Chemotherapy in Patients With Colorectal Cancer and Its Effects on Brain-Gut Peptides, Intestinal Flora, and Oxidative Stress
title Application of Bevacizumab Combined With Chemotherapy in Patients With Colorectal Cancer and Its Effects on Brain-Gut Peptides, Intestinal Flora, and Oxidative Stress
title_full Application of Bevacizumab Combined With Chemotherapy in Patients With Colorectal Cancer and Its Effects on Brain-Gut Peptides, Intestinal Flora, and Oxidative Stress
title_fullStr Application of Bevacizumab Combined With Chemotherapy in Patients With Colorectal Cancer and Its Effects on Brain-Gut Peptides, Intestinal Flora, and Oxidative Stress
title_full_unstemmed Application of Bevacizumab Combined With Chemotherapy in Patients With Colorectal Cancer and Its Effects on Brain-Gut Peptides, Intestinal Flora, and Oxidative Stress
title_short Application of Bevacizumab Combined With Chemotherapy in Patients With Colorectal Cancer and Its Effects on Brain-Gut Peptides, Intestinal Flora, and Oxidative Stress
title_sort application of bevacizumab combined with chemotherapy in patients with colorectal cancer and its effects on brain-gut peptides, intestinal flora, and oxidative stress
topic Surgery
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035672/
https://www.ncbi.nlm.nih.gov/pubmed/35478726
http://dx.doi.org/10.3389/fsurg.2022.872112
work_keys_str_mv AT chenchao applicationofbevacizumabcombinedwithchemotherapyinpatientswithcolorectalcanceranditseffectsonbraingutpeptidesintestinalfloraandoxidativestress
AT housongtao applicationofbevacizumabcombinedwithchemotherapyinpatientswithcolorectalcanceranditseffectsonbraingutpeptidesintestinalfloraandoxidativestress
AT zhaofei applicationofbevacizumabcombinedwithchemotherapyinpatientswithcolorectalcanceranditseffectsonbraingutpeptidesintestinalfloraandoxidativestress
AT wubin applicationofbevacizumabcombinedwithchemotherapyinpatientswithcolorectalcanceranditseffectsonbraingutpeptidesintestinalfloraandoxidativestress
AT liutingting applicationofbevacizumabcombinedwithchemotherapyinpatientswithcolorectalcanceranditseffectsonbraingutpeptidesintestinalfloraandoxidativestress
AT zhangzhao applicationofbevacizumabcombinedwithchemotherapyinpatientswithcolorectalcanceranditseffectsonbraingutpeptidesintestinalfloraandoxidativestress
AT liyuwei applicationofbevacizumabcombinedwithchemotherapyinpatientswithcolorectalcanceranditseffectsonbraingutpeptidesintestinalfloraandoxidativestress
AT lihongchao applicationofbevacizumabcombinedwithchemotherapyinpatientswithcolorectalcanceranditseffectsonbraingutpeptidesintestinalfloraandoxidativestress